Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 650 shares at $5.31 ($3K) on 2013-03-27, disclosed to the SEC on 2013-03-28.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.31 | 500 | $3K | 76.8% |
| 2 | $5.34 | 50 | $267 | 7.7% |
| 3 | $5.36 | 100 | $536 | 15.5% |
| Total | $5.32 avg | 650 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-20 | $23K | — | Filing → |